Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of us oncology research trial 9735
Stephen Jones, Frankie Ann Holmes, Joyce O'Shaughnessy, Joanne L. Blum, Svetislava J. Vukelja, Kristi J. Mclntyre, John E. Pippen, James H. Bordelon, Robert L. Kirby, John Sandbach, William J. Hyman, Donald A. Richards, Robert G. Mennel, Kristi A. Boehm, Wally G. Meyer, Lina Asmar, Daniel Mackey, Stefan Riedel, Hyman Muss, Michael A. Savin
Purpose We previously reported that four cycles of docetaxel/ cyclophosphamide (TC) produced superior disease-free survival (DFS) compared with four cycles of doxorubicin/cyclophosphamide (AC) in early breast cancer. Older women are under-represented in adjuvant chemotherapy trials. In our trial 16% of patients were ≥ 65 years. We now report 7-year results for DFS and overall survival (OS) as well as the impact of age, hormone receptor status, and HEH2 status on outcome and toxicity. Patients and Methods Patients were randomly assigned to receive either four cycles of standard-dose AC (60/600 mg/m2; n = 510), or TC (75/600 mg/m2; n = 506), administered by intravenous infusion every 3 weeks. Results The median age in women younger than 65, was 50 years (range, 27 to 64) and for women ≥ 65 was 69 years (range, 65 to 77). Baseline characteristics in the two age subgroups were generally well matched, except that older women tended to have more lymph node involvement. At a median of 7 years follow-up, the difference in DFS between TC and AC was significant (81 % TC v 75% AC; P =.033; hazard ratio [HR], 0.74; 95% CI 0.56 to 0.98) as was OS (87% TC v 82% AC; P =.032; HR, 0.69; 95% CI, 0.50 to 0.97). TC was superior in older patients as well as younger patients. There was no interaction of hormone-receptor status or HER-2 status and treatment. Older women experienced more febrile neutropenia with TC and more anemia with AC. Conclusion With longer follow-up, four cycles of TC was superior to standard AC (DFS and OS) and was a tolerable regimen in both older and younger patients.
https://doi.org/10.1200/JCO.2008.18.4028
10.1200/JCO.2008.18.4028
Dive into the research topics of 'Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of us oncology research trial 9735'. Together they form a unique fingerprint.
Docetaxel Medicine & Life Sciences 100%
Cyclophosphamide Medicine & Life Sciences 83%
Doxorubicin Medicine & Life Sciences 82%
Disease-Free Survival Medicine & Life Sciences 56%
Survival Medicine & Life Sciences 49%
Hormones Medicine & Life Sciences 21%
Febrile Neutropenia Medicine & Life Sciences 18%
Adjuvant Chemotherapy Medicine & Life Sciences 15%
Jones, S., Holmes, F. A., O'Shaughnessy, J., Blum, J. L., Vukelja, S. J., Mclntyre, K. J., Pippen, J. E., Bordelon, J. H., Kirby, R. L., Sandbach, J., Hyman, W. J., Richards, D. A., Mennel, R. G., Boehm, K. A., Meyer, W. G., Asmar, L., Mackey, D., Riedel, S., Muss, H., & Savin, M. A. (2009). Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of us oncology research trial 9735. Journal of Clinical Oncology, 27(8), 1177-1183. https://doi.org/10.1200/JCO.2008.18.4028
Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide : 7-year follow-up of us oncology research trial 9735. / Jones, Stephen; Holmes, Frankie Ann; O'Shaughnessy, Joyce et al.
In: Journal of Clinical Oncology, Vol. 27, No. 8, 10.03.2009, p. 1177-1183.
Jones, S, Holmes, FA, O'Shaughnessy, J, Blum, JL, Vukelja, SJ, Mclntyre, KJ, Pippen, JE, Bordelon, JH, Kirby, RL, Sandbach, J, Hyman, WJ, Richards, DA, Mennel, RG, Boehm, KA, Meyer, WG, Asmar, L, Mackey, D, Riedel, S, Muss, H & Savin, MA 2009, 'Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of us oncology research trial 9735', Journal of Clinical Oncology, vol. 27, no. 8, pp. 1177-1183. https://doi.org/10.1200/JCO.2008.18.4028
Jones S, Holmes FA, O'Shaughnessy J, Blum JL, Vukelja SJ, Mclntyre KJ et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of us oncology research trial 9735. Journal of Clinical Oncology. 2009 Mar 10;27(8):1177-1183. doi: 10.1200/JCO.2008.18.4028
Jones, Stephen ; Holmes, Frankie Ann ; O'Shaughnessy, Joyce et al. / Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide : 7-year follow-up of us oncology research trial 9735. In: Journal of Clinical Oncology. 2009 ; Vol. 27, No. 8. pp. 1177-1183.
@article{c39794b8798447a0ab8506962a076767,
title = "Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of us oncology research trial 9735",
abstract = "Purpose We previously reported that four cycles of docetaxel/ cyclophosphamide (TC) produced superior disease-free survival (DFS) compared with four cycles of doxorubicin/cyclophosphamide (AC) in early breast cancer. Older women are under-represented in adjuvant chemotherapy trials. In our trial 16% of patients were ≥ 65 years. We now report 7-year results for DFS and overall survival (OS) as well as the impact of age, hormone receptor status, and HEH2 status on outcome and toxicity. Patients and Methods Patients were randomly assigned to receive either four cycles of standard-dose AC (60/600 mg/m2; n = 510), or TC (75/600 mg/m2; n = 506), administered by intravenous infusion every 3 weeks. Results The median age in women younger than 65, was 50 years (range, 27 to 64) and for women ≥ 65 was 69 years (range, 65 to 77). Baseline characteristics in the two age subgroups were generally well matched, except that older women tended to have more lymph node involvement. At a median of 7 years follow-up, the difference in DFS between TC and AC was significant (81 % TC v 75% AC; P =.033; hazard ratio [HR], 0.74; 95% CI 0.56 to 0.98) as was OS (87% TC v 82% AC; P =.032; HR, 0.69; 95% CI, 0.50 to 0.97). TC was superior in older patients as well as younger patients. There was no interaction of hormone-receptor status or HER-2 status and treatment. Older women experienced more febrile neutropenia with TC and more anemia with AC. Conclusion With longer follow-up, four cycles of TC was superior to standard AC (DFS and OS) and was a tolerable regimen in both older and younger patients.",
author = "Stephen Jones and Holmes, {Frankie Ann} and Joyce O'Shaughnessy and Blum, {Joanne L.} and Vukelja, {Svetislava J.} and Mclntyre, {Kristi J.} and Pippen, {John E.} and Bordelon, {James H.} and Kirby, {Robert L.} and John Sandbach and Hyman, {William J.} and Richards, {Donald A.} and Mennel, {Robert G.} and Boehm, {Kristi A.} and Meyer, {Wally G.} and Lina Asmar and Daniel Mackey and Stefan Riedel and Hyman Muss and Savin, {Michael A.}",
doi = "10.1200/JCO.2008.18.4028",
journal = "Journal of Clinical Oncology",
publisher = "American Society of Clinical Oncology",
T1 - Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide
T2 - 7-year follow-up of us oncology research trial 9735
AU - Jones, Stephen
AU - Holmes, Frankie Ann
AU - O'Shaughnessy, Joyce
AU - Blum, Joanne L.
AU - Vukelja, Svetislava J.
AU - Mclntyre, Kristi J.
AU - Pippen, John E.
AU - Bordelon, James H.
AU - Kirby, Robert L.
AU - Sandbach, John
AU - Hyman, William J.
AU - Richards, Donald A.
AU - Mennel, Robert G.
AU - Boehm, Kristi A.
AU - Meyer, Wally G.
AU - Asmar, Lina
AU - Mackey, Daniel
AU - Riedel, Stefan
AU - Muss, Hyman
AU - Savin, Michael A.
N2 - Purpose We previously reported that four cycles of docetaxel/ cyclophosphamide (TC) produced superior disease-free survival (DFS) compared with four cycles of doxorubicin/cyclophosphamide (AC) in early breast cancer. Older women are under-represented in adjuvant chemotherapy trials. In our trial 16% of patients were ≥ 65 years. We now report 7-year results for DFS and overall survival (OS) as well as the impact of age, hormone receptor status, and HEH2 status on outcome and toxicity. Patients and Methods Patients were randomly assigned to receive either four cycles of standard-dose AC (60/600 mg/m2; n = 510), or TC (75/600 mg/m2; n = 506), administered by intravenous infusion every 3 weeks. Results The median age in women younger than 65, was 50 years (range, 27 to 64) and for women ≥ 65 was 69 years (range, 65 to 77). Baseline characteristics in the two age subgroups were generally well matched, except that older women tended to have more lymph node involvement. At a median of 7 years follow-up, the difference in DFS between TC and AC was significant (81 % TC v 75% AC; P =.033; hazard ratio [HR], 0.74; 95% CI 0.56 to 0.98) as was OS (87% TC v 82% AC; P =.032; HR, 0.69; 95% CI, 0.50 to 0.97). TC was superior in older patients as well as younger patients. There was no interaction of hormone-receptor status or HER-2 status and treatment. Older women experienced more febrile neutropenia with TC and more anemia with AC. Conclusion With longer follow-up, four cycles of TC was superior to standard AC (DFS and OS) and was a tolerable regimen in both older and younger patients.
AB - Purpose We previously reported that four cycles of docetaxel/ cyclophosphamide (TC) produced superior disease-free survival (DFS) compared with four cycles of doxorubicin/cyclophosphamide (AC) in early breast cancer. Older women are under-represented in adjuvant chemotherapy trials. In our trial 16% of patients were ≥ 65 years. We now report 7-year results for DFS and overall survival (OS) as well as the impact of age, hormone receptor status, and HEH2 status on outcome and toxicity. Patients and Methods Patients were randomly assigned to receive either four cycles of standard-dose AC (60/600 mg/m2; n = 510), or TC (75/600 mg/m2; n = 506), administered by intravenous infusion every 3 weeks. Results The median age in women younger than 65, was 50 years (range, 27 to 64) and for women ≥ 65 was 69 years (range, 65 to 77). Baseline characteristics in the two age subgroups were generally well matched, except that older women tended to have more lymph node involvement. At a median of 7 years follow-up, the difference in DFS between TC and AC was significant (81 % TC v 75% AC; P =.033; hazard ratio [HR], 0.74; 95% CI 0.56 to 0.98) as was OS (87% TC v 82% AC; P =.032; HR, 0.69; 95% CI, 0.50 to 0.97). TC was superior in older patients as well as younger patients. There was no interaction of hormone-receptor status or HER-2 status and treatment. Older women experienced more febrile neutropenia with TC and more anemia with AC. Conclusion With longer follow-up, four cycles of TC was superior to standard AC (DFS and OS) and was a tolerable regimen in both older and younger patients.
U2 - 10.1200/JCO.2008.18.4028
DO - 10.1200/JCO.2008.18.4028
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology